News & Videos - NEOVACS - English - Page 2

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs announces in vivo Proof of Concept success for its IL-4 / IL-13 Kinoid a new Therapeutic Vaccine to treat Mite-induced Asthma IL-4 / IL-13 Kinoid induces strong production of neutralizing antibodies against cytokines IL-4 and IL-13 and inhibits bronchoconstriction These results will help to define the future development in this indication in order to provide patients with long-term protection against allergic diseases. Paris and Boston,...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE HALF-YEAR 2018 FINANCIAL RESULTS STRENGTHENED CASH POSITION: € 4.7 M AT JUNE 30 2018 VS € 1.7 M AT JUNE 30 2017 LOWER OPERATING COSTS, CONSISTENT WITH THE END OF THE IFNalpha KINOID PHASE IIB STUDY FOR LUPUS TREATMENT NET LOSS REDUCED BY 25% 2019 DEVELOPMENT PLAN CONFIRMED Paris, Boston, October 30, 2018, 05h50pm CET - NEOVACS (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, provided...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THE CONTINUATION OF THE DEVELOPMENT OF ITS IFN alpha KINOID IN SOUTH KOREA WITH ITS PARTNER CHONG KUN DANG (CKD) PHARMACEUTICALS Both partners have agreed to prepare the filing for an Orphan Drug Designation (ODD) Paris and Boston, the 11 th of October 2018 - 07:00 AM CEST- Neovacs (Euronext Growth Paris ALNEV), leader in active immunotherapy for the treatment of auto-immune diseases, today announces the continuation of the...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS EXERCISED ITS OPTION TO ACQUIRE THE EXCLUSIVE LICENCE FOR IFNalpha KINOID TO TREAT LUPUS IN CHINA Paris and Boston, 11 September 2018 - 07H00am CEST- Neovacs (Euronext Growth Paris ALNEV), leader in active immunotherapy for the treatment of auto-immune diseases, today announces that its partner Biosense Global has exercised its option as stipulated in the license agreement signed on February...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFN alpha KINOID IN THE TREATMENT OF LUPUS WHICH ALLOWS TO PROCEED WITH THE CLINICAL DEVELOPMENT INTO PHASE III THE BIOLOGICAL OBJECTIVE AND THREE OUT OF FOUR CLINICAL OBJECTIVES WERE MET: Highly statistically significant efficacy in reduction of interferon signature Lack of statistically significant clinical efficacy measured by BICLA [1] score Statistical trend on clinical efficacy measured...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS STRENGTHENS INTELLECTUAL PROPERTY POSITION IN EUROPE AND JAPAN Newly issued patent covers IFNalpha Kinoid and its application in all diseases related to an overproduction of IFNalpha cytokine Paris and Boston, May 15 th , 2018, 18:00 pm CEST - Neovacs (Euronext Growth Paris: ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that the patent entitled, "Method for treating Interferon alpha...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS PROVIDES CORPORATE UPDATE AND REPORTS FULL-YEAR 2017 FINANCIAL RESULTS COMPLETED PATIENT ENROLLMENT IN PHASE IIb CLINICAL STUDY OF IFNalpha KINOID FOR TREATMENT OF LUPUS RECEIVED U.S. FDA APPROVAL TO EXPAND ITS PHASE I/IIa CLINICAL STUDY WITH IFNalpha KINOID FOR TREATMENT OF DERMATOMYOSITIS STRENGTHENED BALANCE SHEET THROUGH TWO TRANSACTIONS RESULTING IN APPROXIMATELY €11MILLION LAUNCH OF A REDEEMABLE STOCK WARRANT (BSAR) FREE ALLOCATION...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS STRENGTHENS ITS INTELLECTUAL PROPERTY IN THE USA This patent covers IFNalpha Kinoid and its application in all diseases related to an overproduction of IFNalpha cytokine Paris and Boston, February 22 nd 2018, 07:00 am CET - Neovacs (Euronext Growth Paris: ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it has been granted by the United States Patent and Trademark Office (USPTO) the...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE 2018 Financial Calendar Paris, February 16, 2018, 6pm CET - NEOVACS (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, annonced today its financial reporting calendar for 2018. Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change. Shareholders AGM- 1 st convocation February 28, 2018 Shareholders AGM - 2...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs Announces Positive Data Review from Last IDSMB Review Prior to Final Results of Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus Final Trial Results Expected in June 2018 Paris and Boston, February 13 th 2018, 07:00 am CET - Neovacs (Euronext Growth: ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it has received a positive data review from the Independent Data and Safety...

NEOVACS STRENGTHENED ITS INTELLECTUAL PROPERTY IN RUSSIA This patent covers IFNalpha kinoid and its application in all diseases related to an overproduction of IFNalpha cytokine Paris and Boston, January 16 th 2018, 07:00 am CET - Neovacs ( Euronext Growth Paris: ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases , today announces that it has been granted a new patent from the Russian Federation Patent Office (ROSPATENT), titled: "Method of treatment of a disease...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES POSITIVE RESULTS OF PRECLINICAL STUDY FOR IFNalpha KINOID IN TYPE 1 DIABETES Company intends to continue preclinical development in this indication in 2018 Paris and Boston, December 12 th 2017, 07:00 am CET - Neovacs (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced positive initial results from its ongoing proof-of-concept (PoC) preclinical studies with...

This is a correction of the announcement from 17:45 27.10.2017 CEST. Reason for the correction:the release date of the data for Type 1 Diabete preclicical proof of concept remains unchanged compared to previous annoucements, Neovacs will publich these data before the end of 2017.* PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS COMPLETED PATIENT ENROLLMENT IN PHASE IIb CLINICAL STUDY OF IFNalpha KINOID FOR TREATMENT...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS COMPLETED PATIENT ENROLLMENT IN PHASE IIb CLINICAL STUDY OF IFNalpha KINOID FOR TREATMENT OF LUPUS RECEIVED U.S. FDA APPROVAL TO EXPAND ITS PHASE I/IIa CLINICAL STUDY WITH IFNalpha KINOID FOR TREATMENT OF DERMATOMYOSITIS STRENGTHENED BALANCE SHEET THROUGH TWO TRANSACTIONS RESULTING IN APPROXIMATELY €10 MILLION Paris, October 27, 2017 , 5:45pm CET - NEOVACS (Alternext...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THE CLOSING OF A €6.0 MILLION PRIVATE PLACEMENT WITH U.S. BIOTECHNOLOGY INSTITUTIONAL INVESTORS Paris and Boston, August 4, 2017 - 5:45 pm CET - Neovacs (Euronext Growth: ALNEV), (the "Company") a leader in active immunotherapies for the treatment of autoimmune diseases, today confirmed the successful closing of the 6.0 million euros share capital increase by private placement with U.S. institutional investors active in the...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS SUCCESSFULLY RAISES € 6.0 MILLION IN PRIVATE PLACEMENT WITH U.S. BIOTECHNOLOGY INSTITUTIONAL INVESTORS Paris and Boston, July 31, 2017 - 7:30 am CET - Neovacs (Euronext Growth Paris: ALNEV), (the "Company") a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that it has received commitments from U.S. institutional investors for a capital increase totaling €6.0 million in the context of a private...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs Announces FDA Acceptance of a New IND to Expand in U.S. IFNalpha Kinoid Clinical Development Program in Dermatomyositis This is the second clinical trial approved by the FDA for Neovacs' lead product candidate Paris and Boston, July 19 th , 2017 - 7:30 am CET - Neovacs (Euronext Growth Paris: ALNEV) a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA)...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs Announces Positive IDSMB Review for Phase IIb Clinical Trial of IFNalpha Kinoid in Lupus Third positive data review by IDSMB follows completion of patient recruitment Paris and Boston, July 11 th , 2017 - 7:30 am CET - Neovacs (Euronext Growth: ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it received a positive data review by the Independent Data and Safety Monitoring Board (IDSMB)...

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFNalpha KINOID FOR TREATMENT OF LUPUS IN TURKEY Agreement grants Centurion Pharma exclusive license to market IFNalpha Kinoid in Turkey Paris and Boston, July 5th, 2017 - 7:00 AM CET - Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that the Company has signed an exclusive license agreement for IFNalpha Kinoid for the treatment of...

NEOVACS ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL STUDY OF IFNalpha KINOID IN LUPUS Company Expects the Availability of Results from the Study in Q2 2018 Paris and Boston, June 20, 2017 - 7:00 AM CET - Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the completion of patient enrollment for its phase IIb clinical study, IFN-K-002, evaluating IFNalpha Kinoid for the treatment of lupus. " The...